Chaffetz on drug price increases before the patent cliff

As to Congressman Chaffetz, Investors Business Daily noted:



a group of congressional Democrats sent a letter to Rep. Jason Chaffetz, chair of the House Committee on Oversight and Government Reform, requesting a subpoena to make Valeant turn over documents related to last February's triple-digit price increases on two heart drugs, Nitropress and Isuprel.



Link to Investor's Business Daily article, Valeant Defended After Politics-Induced Sell-Off: http://news.investors.com/technology/092915-773226-valeant-stock-seen-as-buying-opportunity.htm#ixzz3nM3pMhli

IBD was somewhat cool on the idea of Chaffetz favorably responding to Democrats, but IPBiz notes Chaffetz is a different type of chairman.

From realclearpolitics :



When Chaffetz campaigned to run the committee in the new Congress – Issa was forced to leave because of Republican term limits on chairmanships – the Utah lawmaker ran partially on a platform of taking the committee in a new, less fiery direction, promising improved relationships with Democrats. And in the first six months, the reviews of Chaffetz’s nascent tenure are positive across the board, and across the aisle.


And Chaffetz gets along well with Elijah Cummings.